AI
Wednesday, June 21, 2023 10:30:45 AM
Smitty5150,
Thanks for the reply.
I don't anticipate NW will get acquired. One simple reason is that the price tag is far too high and no BP can afford it.
Merck bought Prometheus for $11b which potentially will deliver a drug for two diseases with market size of $23b in 2022. The market for solid tumors could be ten or twenty times of this two specific rare diseases. I am confident that 8000% gain or even higher will happen to your NWBO investment.
My understanding about Professor Esteban Celis said about immunotherapy?
1. It is very hard to get T-cells to tumor site.
>> DCVax-L has overcome this issue.
2. Even T-cells can reach tumor site, without right adjuvant, the immune response will not be strong.
>>DCVax-L has the right adjuvant to maturate and excite the dendritic cells carrying hundreds or thousands of tumor-associate antigens.
https://s21.q4cdn.com/488056881/files/doc_presentations/2023/04/Splash-Investor-Event-Slides-FINAL-1.pdf
Thanks for the reply.
I don't anticipate NW will get acquired. One simple reason is that the price tag is far too high and no BP can afford it.
Merck bought Prometheus for $11b which potentially will deliver a drug for two diseases with market size of $23b in 2022. The market for solid tumors could be ten or twenty times of this two specific rare diseases. I am confident that 8000% gain or even higher will happen to your NWBO investment.
My understanding about Professor Esteban Celis said about immunotherapy?
1. It is very hard to get T-cells to tumor site.
>> DCVax-L has overcome this issue.
2. Even T-cells can reach tumor site, without right adjuvant, the immune response will not be strong.
>>DCVax-L has the right adjuvant to maturate and excite the dendritic cells carrying hundreds or thousands of tumor-associate antigens.
https://s21.q4cdn.com/488056881/files/doc_presentations/2023/04/Splash-Investor-Event-Slides-FINAL-1.pdf
